Study to assess the safety and efficacy of AMG-145 in combination with Statin therapy in patients with high blood cholesterol or high concentration of lipids in the blood To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 administered every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from ...

• Country None
• organs None
• Specialty None

Pembrolizumab With or Without Talimogene Laherparepvec in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab con o sin Talimogene Laherparepvec en Carcinoma de Células Escamosas de Cabeza y Cuello Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in subjects with SCCHN. Phase 3: To evaluate...

• Country None
• organs None
• Specialty None

Study to Evaluate Darbepoetin alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease To evaluate the safety and tolerability of darbepoetin alfa following single 1.5 microgram/kg subcutaneous (SC) dose administration in paediatric subjects < 1 year of age with anaemia due to chronic k...

• Country None
• organs None
• Specialty None

Darbepoetin alfa in Anaemic Subjects With Low Risk Myelodysplastic Syndromes - Companion Study To provide required access of investigational product (darbepoetin alfa) beyond the end of active treatment period of the Darbepoetin alfa MDS 20090160 study for subjects that have continued demonstra...

• Country None
• organs None
• Specialty None

An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) To evaluate the safety and tolerability of AMG 531 in thrombocytopenic subjects with low or Intermediate-1 risk MDS.

• Country None
• organs None
• Specialty None

A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy To evaluate the safety, tolerability and pharmacokinetics (PK) of AMG 114 administered subcutaneously for the treatment of chemotherapy induced anemia in subjects receiving multicycle chemotherapy

• Country None
• organs None
• Specialty None

A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer. ---------------------------------------------------------------------------------------------------- Ensayo aleatorizado de fase 1b/2 de AMG 102 o AMG 479 en combinación con panitumumab frente a panitumumab en monoterapia en sujetos con cáncer colorrectal metastásico con KRAS no mutado Part 1: To identify a tolerable dose of AMG 102 in combination with panitumumab based on the incidence of dose-limiting toxicities (DLTs) Part 2: To evaluate the efficacy as assessed by the overal...

• Country None
• organs None
• Specialty None

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction ...

• Country None
• organs None
• Specialty None

A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopathic) Thrombocytopenic Purpura The objective of the study is to compare the ability of AMG 531 versus medical standard of care (SOC) to prevent a splenectomy and to provide a durable treatment option for immune (idiopathic) thrombo...

• Country None
• organs None
• Specialty None

This trial is designed to determine the effects the investigational medicine, ABP 798 has on the human body , and what effects the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe rheumatoid arthritis (RA). This study will assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine The primary objective for this study is to demonstrate pharmacokinetic (PK) similarity of ABP 798 following 2 intravenous (IV) infusions of 1000 mg each, relative to that of 2 IV infusions of 1000 mg ...

• Country None
• organs None
• Specialty None